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Abstract 
Background: Hodgkin lymphoma is a systemic disease that commonly involves the cervical, supraclavicular, and 
mediastinal lymph nodes. The involvement of central nervous system in Hodgkin lymphoma is extremely rare, and 
diagnosis is usually established using distinct morphological and immunohistochemical staining on the tissue biop-
sied. Extranodal presentation of HL is a rare occurrence. It has been evident that prognosis is encouraging in patients 
with disease that is limited to just central nervous system initially or as relapse, compared with involvement of multi-
ple sites of relapse.
Case presentation: We herein report a case of a 35-year-old South-East Asian male with relapsed Hodgkin lym-
phoma. The patient developed a parotid gland lesion, cervical lymphadenopathy with significant weight loss, and 
intermittent night sweats. Along with spread to the central nervous system, there was a high suspicion of tuberculo-
sis. Upon biopsy of his cervical lymph node, the patient was confirmed to have Hodgkin lymphoma. Immediate treat-
ment began with six cycles of chemotherapy consisting of adriamycin, bleomycin, vinblastine, and dacarbazine. The 
patient received three cycles of chemotherapy consisting of ifosfamide, carboplatin, and etoposide but then was lost 
to follow-up. Five years later, the patient suffered a road traffic accident. Upon work-up, a right parietal space-occu-
pying lesion with moderate cerebral edema and midline shift was found on computed tomography of the brain. The 
patient underwent resection of the space-occupying lesion of brain, with features consistent with classical Hodgkin 
lymphoma on histopathology examination. It is crucial for such lesions to be investigated meticulously to rule out any 
secondary disease process.
Conclusion: Relapsed Hodgkin lymphoma with central nervous system involvement is relatively rare with just over 
two dozen cases reported to date and is observed infrequently in developing nations. Therefore, space-occupying 
lesion should always be investigated, and biopsy of such lesions is gold standard to establish diagnosis. With timely 
appropriate therapy, complete remission can be achieved. However, large-scale studies would be prudent to explore 
the presentation, survival, and treatment options for patients with Hodgkin lymphoma involving the central nervous 
system.
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Background
Classic Hodgkin lymphoma (HL) is a cancer of the lym-
phatic system and primarily affects lymph nodes. As 
compared with non-Hodgkin lymphoma (NHL), central 
nervous system (CNS) involvement in HL is extremely 
rare, recently shown to occur in less than 0.2–0.5% of 
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HL patients [1] whereas CNS involvement can be found 
in up to 5–30% of NHL patients [2]. Nodular sclerosis 
and mixed cellularity are the most commonly seen his-
tological subtypes of HL that occur in relapsed disease. 
Treatment modalities include radiotherapy alone or in 
combination with chemotherapy. We describe a patient 
with classic HL presenting with relapse of disease in 
the brain. The rare occurrence and paucity of avail-
able reports on such presentation make it a challenging 
diagnosis for physicians. Moreover, these presentations 
can prove to be a puzzling conundrum for physicians in 
low-middle-income countries where timely diagnosis 
and management can relieve the existing burden on the 
under-resourced healthcare.
Case presentation
A 35-year-old South-East Asian male, nonsmoker, with 
no known comorbidities, reported to outpatient facility 
in 2012, when he developed right parotid swelling and 
was managed conservatively. His swelling later trans-
formed into an ulceration. He took multiple courses of 
antibiotics prescribed by general physicians and also used 
medication given by unqualified practitioners . Family 
history was negative for any malignancies. The patient 
belonged to a household of low socioeconomic status, 
being employed as a domestic worker. In a few months’ 
time, the patient developed progressive cervical lym-
phadenopathy with significant weight loss and intermit-
tent night sweats. Due to high prevalence of tuberculosis 
in the local population, the patient underwent antituber-
culosis treatment (ATT) consisting of rifampicin (10 mg/
kg), isoniazid (5  mg/kg), ethambutol (15  mg/kg), and 
pyrazinamide (25 mg/kg). However, no signs of improve-
ment were observed after treatment for 2 months. Dur-
ing this time period, he developed an ulcerated lesion of 
the right parotid gland. Biopsy of the cervical lymph node 
revealed Hodgkin lymphoma, and the patient underwent 
six cycles of chemotherapy ABVD [adriamycin (25  mg/
m2 intravenous), bleomycin (10 U/m2 intravenous), vin-
blastine (6 mg/m2 intravenous), and dacarbazine (DTIC) 
(375 mg/m2 intravenous)]. Each cycle was repeated every 
28 days, and this combination was administered on day 1 
and day 15. No significant reduction in size of the lymph 
nodes was observed after chemotherapy, and his parotid 
gland lesion remained unchanged. Later in June 2013, 
a biopsy of the ulcerated parotid gland lesion was per-
formed with findings that were consistent with Hodgkin 
lymphoma. He received his second-line chemotherapy: 
three cycles of dexamethasone, high-dose Ara-C, and 
platinol (DHAP). Staging computed tomography (CT) 
was performed to evaluate the response of treatment, 
which showed no interval change in parotid lesion but a 
significant reduction in the size of cervical lymph nodes. 
Furthermore, 25 fractions of radiation therapy were 
administered to the patient at the right side of his face 
including right side of neck. After 10  months of treat-
ment, disease progression was still observed with com-
plaint of cervical lymphadenopathy. In 2014, the patient 
received three cycles of chemotherapy consisting of ifos-
famide, carboplatin, and etoposide (ICE). The patient 
demonstrated noncompliance to further treatment 
options and regular hospital visits because of financial 
constraints, and was eventually lost to follow-up.
In 2019, the patient suffered a road traffic accident 
(RTA) after 5  years of disease. The cause of RTA was 
identified as loss of consciousness (LOC) as confirmed by 
the patient’s brother, who was with him during the acci-
dent. A right parietal well-circumscribed space-occupy-
ing lesion of around 6.7 × 4.9 cm with moderate cerebral 
edema and midline shift was found on CT brain imaging 
as shown in Fig. 1. He regained his consciousness sponta-
neously after a few hours in the emergency department. 
On further questioning, the patient described intermit-
tent mild headaches a few months prior to the accident. 
His general physical examination was normal, with few 
marks of skin abrasions on his limbs. His lab workup 
was also unremarkable. He was scheduled for elective 
surgery and eventually underwent a gross total resec-
tion of the space-occupying lesion of brain. The speci-
men was sent for analysis, and immunohistochemistry 
revealed atypical cell infiltrates largely positive for CD30, 
CD15, and weakly positive PAX5 but lack of expression 
for LCA, CD20, and CD3 as shown in Fig. 2. Surprisingly, 
these features were consistent with classical Hodgkin 
lymphoma according to the World Health Organization 
(WHO) classification of lymphoid neoplasm. The patient 
was reported to be alive and recovering well post-sur-
gery during hospital follow-ups and was also advised to 
see medical oncology for further cancer treatment. His 
parotid gland ulceration responded to radiation ther-
apy and very much regressed when he presented with 
lymphadenopathy for the third time and received three 
cycles of ICE. Unfortunately, he never showed up and 
died after 4 months of his surgery, likely due to untreated 
underlying cancer. Informed consent was obtained from 
the patient’s uncle for the use of images and details for 
reporting the case for publication and teaching purposes.
Discussion
Central nervous system involvement is rare with HL, 
accounting for 0.2–0.5% of all cases [1], and mostly 
occurs as a relapse. Due to the rare occurrence, only 
22 cases to date have been reported in the literature [1, 
3–5]. In contrast, CNS involvement is 5–30% in patients 
with NHL [2]. Classical HL primarily affects the lymph 
nodes as neurological sequelae rarely occur. However, 
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neurological complications can occur due to metastatic 
disease, occurring as paraneoplastic phenomena, or 
treatment-induced neurological complication [6]. Some 
of the paraneoplastic manifestations include degenera-
tion of cerebellum, chorea, demyelinating polyradicu-
lopathy, and myasthenia gravis. Therapeutic radiation 
can lead to neurologic complications such as dropped 
head syndrome, acute brachial plexopathy, and intracra-
nial infarction. Furthermore, chemotherapy for Hodgkin 
lymphoma may cause peripheral neuropathy and cerebral 
infarction possibly due to drug-induced embolism [7].
Most research studies state the location of the lesion 
to be supratentorial [8]. Several risk factors are respon-
sible for disease relapse such as male gender, positive 
family history, immunosuppressed state, and infection 
with Epstein–Barr virus (EBV) [9]. In our case, tubercu-
losis was suspected since its coexistence with HL is well 
reported, resulting from two potential processes: T-cell 
dysfunction related to HL, and B-cell immune dysfunc-
tion resulting from HL therapy [10]. Tuberculosis and HL 
can both involve the CNS, but to date, there is no litera-
ture that correlates an increased risk of CNS tuberculosis 
with HL.
HL can affect CNS in several ways, including skull 
contiguity, meningeal invasion, or through the hematog-
enous route, which is the most common route of spread 
[11]. Some of the common manifestations of intracranial 
involvement include cranial nerve palsies, with other 
signs and symptoms such as headaches, papilledema, 
paresis, seizures, and other neurological manifestations 
[12]. In our case, the patient had a history of headaches 
and an episode of loss of consciousness. Nodular scle-
rosis and mixed cellularity are the most commonly seen 
histological subtypes of HL that occur in relapsed dis-
ease. Moreover, the presence of Reed–Sternberg cells 
and co-expression of CD30 and CD15 antigens with 
lack of CD20 and CD3 strongly support the diagnosis of 
Hodgkin lymphoma [13]. The gold-standard diagnosis is 
biopsy, which is essential for confirmation.
Due to the rare occurrence of this presentation and 
insufficient data from clinical trials, no specific treat-
ment guidelines have been established. Evidence suggests 
a variety of treatment modalities, including radiotherapy 
alone for isolated CNS involvement, or holocranial irra-
diation and combination chemotherapy. In the case of 
meningeal disease, intrathecal methotrexate can be used 
as well [4]. Other previously used modalities include stem 
cell transplantation or surgery. CNS prophylaxis is not 
routinely recommended in HL as more data are needed 
to identify specific populations who could benefit from it 
[14]. It is crucial for prompt screening and diagnosis of 
debilitating complications that have low risk of suspicion 
and paucity of evidence on treatment. Developing an 
appropriate treatment strategy has been challenging due 
to the short median survival of approximately 46 months 
[6] after HL has been diagnosed. It has been observed 
that prognosis is better in patients with disease limited to 
CNS either initially or as relapse, compared with patients 
with evidence of more than one site of relapse [15].
Conclusion
Relapsed Hodgkin lymphoma with CNS involve-
ment is uncommon; therefore, space-occupying lesion 
(SOL) should always be investigated and biopsy of such 
lesions is gold standard to establish diagnosis. With 
timely appropriate therapy, complete remission can be 
Fig. 1 Radiographical presentation showing space-occupying lesion in right parietal region
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achieved. However large-scale studies are still needed 
to understand the presentation, survival, and treatment 
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